Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial

The Lancet Diabetes & Endocrinology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles